• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Bausch + Lomb Corporation

    5/30/25 4:14:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    SD 1 formsd-2024blconflictminer.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM SD
    SPECIALIZED DISCLOSURE REPORT
    BAUSCH + LOMB CORPORATION
    (Exact name of the registrant as specified in its charter)
    Canada
    001-41380
    98-1613662
    (State or other jurisdiction of incorporation or organization)
    (Commission File Number)
    (IRS Employer Identification No.)
    520 Applewood Crescent
    Vaughan, Ontario, Canada L4K 4B4
    (Address of principal executive offices)

    Alex Matheson
    Senior Vice President, Asst. General Counsel
    (908) 927-1164
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
    X    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.












    Section 1 — Conflict Minerals Disclosure
    Item 1.01 Conflict Minerals Disclosure and Report
    Conflict Minerals Disclosure
    The Bausch + Lomb Corporation Conflict Minerals Report for the calendar year ended December 31, 2024 filed herewith as Exhibit 1.01, is available at www.bausch.com. The content of our website as referred to in this Form SD is included for general information only and is not incorporated by reference into this Form SD.
    Item 1.02 Exhibit
    The Conflict Minerals Report as required by Item 1.01 is filed as Exhibit 1.01 to this Form.
    Section 2 — Resource Extraction Issuer Disclosure
    Item 2.01 Resource Extraction Issuer Disclosure and Report
    Not applicable.
    Section 3 — Exhibits
    Item 3.01 Exhibits

    Exhibit Number    Description                                    
    1.01            Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
    Bausch + Lomb Corporation
    (Registrant)
    /s/ A. Robert D. Bailey
    Date: May 30, 2025
    By (Signature and Title)
    (Date)
    A. Robert D. Bailey
    Executive Vice President, Chief Legal Officer


    Get the next $BLCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $BLCO
    SEC Filings

    See more
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/18/25 4:52:57 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      6/10/25 9:05:43 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form SD filed by Bausch + Lomb Corporation

      SD - Bausch & Lomb Corp (0001860742) (Filer)

      5/30/25 4:14:06 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, Surgical Bonnefoy Luc covered exercise/tax liability with 968 shares, decreasing direct ownership by 1% to 73,383 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      6/16/25 4:46:45 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. was granted 20,338 shares, increasing direct ownership by 49% to 62,086 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:11:49 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Ross Thomas W. Sr. was granted 20,338 shares, increasing direct ownership by 51% to 60,391 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/28/25 4:10:50 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Bausch + Lomb with a new price target

      H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      5/2/25 7:51:06 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously

      3/28/25 8:14:16 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Citigroup with a new price target

      Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously

      12/11/24 7:25:38 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman of the Board Saunders Brent L bought $248,072 worth of shares (22,000 units at $11.28) and was granted 22,000 shares, increasing direct ownership by 6% to 741,156 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/27/25 8:16:24 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      8/7/24 5:29:48 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 ("Notes"). The size of the offering was increased from the previously announced €600 million aggregate principal amount of Notes. The Notes will be sold to investors at a price of 99.500% of the principal amount thereof. As previously announced, the company is also seeking to partia

      6/18/25 4:30:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the "Issuers"), have launched an offering of €600 million aggregate principal amount of senior secured floating rate notes ("Notes"). In connection with the Notes offering, the company has also launched a partial refinancing of its credit agreement, whereby the company intends to obtain a $2.2 billion new term B loan facility (the "New Term B Loan Facility") and a new $800 million revolving credit facility (the

      6/10/25 8:48:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

      Blink Nourish and Blink Boost are now available at most U.S. national retailers, including Walmart, Target, CVS, Walgreens and Amazon Blink Nourish is the first and only vitamin-enriched preservative-free eye drop designed to replenish and rebalance the tear film Blink Boost's formula is pH-balanced to match healthy tears, making it comfortable when applied Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to

      6/4/25 6:59:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch + Lomb Corporation

      SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

      2/14/23 5:14:30 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

      Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

      5/21/25 4:30:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

      Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

      2/28/24 8:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

      Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

      2/21/24 7:00:00 AM ET
      $BLCO
      $EBS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $BLCO
    Financials

    Live finance-specific insights

    See more
    • Bausch + Lomb Announces First-Quarter 2025 Results

      Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning

      4/30/25 6:57:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date:     Wednesday, April 30, 2025   Time:     8 a.m. ET   Webcast:     https://www.webcaster4.com/Webcast/Page/2883/51713   Participant Event Dial-in:     +

      3/26/25 7:45:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

      Fourth-Quarter 2024 Financial Results Revenue of $1.280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results Revenue of $4.791 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $317 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $878 Million Revenue Grew 16% as Reported and 17% on a Constant Currency1 Basis Compared to the Full Year of 2023, with Growth Across All Segments Baus

      2/19/25 6:58:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care